Figure 1.

Prediction of biochemical recurrence in all prostate cancer patients using two biomarker panels, adjusted for clinical information. A: Kaplan-Meier analysis of the training set patients that were separated based on the mRNA panel described in Table 2. B: Kaplan-Meier analysis on the validation cases using the mRNA panel. C: Kaplan-Meier analysis of the training set using the combined mRNA and miRNA panel described in Table 3. D: Kaplan-Meier analysis of the validation set using the combined mRNA and miRNA panel.